

## Special Issue

# Molecular Pathology and Biomarkers of Neurodegenerative Diseases

### Message from the Guest Editors

Many abiotic stresses induce the overproduction of reactive oxygen species (ROS) in humans. Being highly reactive and toxic species, they cause damage to DNA, proteins, carbohydrates and lipids, thus leading to oxidative stress. The increased production of reactive oxygen species and oxidative stress has been implicated in the pathogenesis of numerous inflammatory and neurodegenerative pathological conditions. The endogenous antioxidant response pathway protects cells from oxidative stress by increasing the expression of cytoprotective enzymes, and is regulated by the transcription factor NRF2. In addition to regulating the expression of antioxidant genes, NRF2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. This Special Issue will focus on the role of NRF2 as a promising therapeutic target for inflammatory and neurodegenerative diseases. In particular, it will be aimed at the discovery of specific NRF2 activators that can be used as therapeutic agents. The Special Issue will feature original in vivo and in vitro reviews and studies providing evidence of the beneficial effects of antioxidant factors.

### Guest Editors

Dr. Tiziana Genovese

Dr. Daniela Impellizzeri

Dr. Rosalba Siracusa

### Deadline for manuscript submissions

closed (31 May 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/112887](https://mdpi.com/si/112887)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).